Human Genome Sciences

M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...

Citadel Securities has published a report on Human Genome Sciences (NASDAQ: HGSI) initiating coverage on the biotech company. In the report, Citadel wrote, "We believe investors and the Street are singularly focused on Benlysta, resulting in the opportunity for potential upside on the “hidden...

Citi provided color on Human Genome Sciences (NASDAQ: HGSI). In a research report published today, Citi commented on the company's testing of new products. In the report, Citi states, “GSK is developing the drug and HGS is eligible to receive royalty payments. Our physician expert was highly...

According to Bank of America, Human Genome Sciences (NASDAQ: HGSI) is rated Underperform. Bank of America said that it found mixed results from our survey of 150 US physicians designed to assess initial market expectations for HGSI/GSK's recently launched lupus drug Benlysta. “Better than expected...

Goldman Sachs reiterated its Hold rating on Human Genome Sciences (NASDAQ: HGSI) after the company launched its new drug Benlysta. In a research report published today, Goldman Sachs states, "The early Benlysta launch appears to be tracking well, but we remain on the sidelines as we believe HGSI...

Seeking Alpha lists Biotech stocks that are currently very cheap, but are anticipating significant growth in the future. Chelsea Therapeutics (NASDAQ: CHTP) is one to watch, Seeking Alpha explains, “Chelsea Therapeutics (CHTP) is trading around $4. CHTP is a biotechnology company, based in North...

According to Piper Jaffray, Human Genome Sciences (NASDAQ: HGSI) held analyst and investor meetings. Piper Jaffray reported that the company provided updates on Benlysta's target population, strategies on facilitating drug access, payer and reimbursement progress, and ongoing and future clinical...

Piper Jaffray has raised the price target on Human Genome Sciences (NASDAQ: HGSI) from $32 to $36 and maintains its Overweight rating.

J.P. Morgan is out with its report today on Human Genome Sciences (NASDAQ: HGSI), maintaining Overweight. In a note to clients, J.P. Morgan writes, "After market close, HGSI announced an in-licensing deal with FivePrime Therapeutics for FP-1039, an FGF fusion protein in Ph1 development for cancer...

J.P. Morgan is reiterating its Overweight rating on shares of Human Genome Sciences Inc. (NASDAQ: HGSI) “following last night's announcement that the FDA approved Benlysta for the treatment of lupus.” “This outcome was widely expected, but we nevertheless view it as a transformative event,” J.P....

Goldman Sachs is raising its PT on shares of Human Genome Sciences Inc. (NASDAQ: HGSI) from $25 to $28. Human Genome Sciences closed Wednesday at $25.68.

The FDA has approved Human Genome Sciences Inc.'s (NASDAQ: HGSI) Benlysta for treatment of patients with active, autoAb-positive systemic lupus erythematosus (SLE) receiving standard therapy, without major restrictions or a black box warning and a limited REMS, Piper Jaffray reports. “This combined...

Piper Jaffray has lowered the price target on Human Genome Sciences (NASDAQ: HGSI) from $40 to $33 and maintains its Overweight rating.

Human Genome Sciences, Inc. (NASDAQ: HGSI) is trading up 1.53%. Shares last traded at $25.20, up from $24.82 at yesterday's close.

Collins Stewart published its research report on Human Genome Sciences (NASDAQ: HGSI) after the FDA announced it would delay the PDUFA on HGSI's Benlysta. In a note to clients, Collins Stewart writes, "removes the risk of a Class 2 resubmission with a 6-month review period. We continue to expect...